

# Impacts of Symptomatic HIV Infection on In-Hospital Cardiopulmonary Resuscitation Outcomes: A Population-Based Cohort Study in South Korea

## Tak Kyu Oh,<sup>1,2,0</sup> You Hwan Jo,<sup>3</sup> Kyoung-Ho Song,<sup>4</sup> and In-Ae Song<sup>1,2</sup>

<sup>1</sup>Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, <sup>2</sup>Department of Anesthesiology and Pain Medicine, College of Medicine, Seoul National University, Seoul, South Korea, <sup>3</sup>Department of Emergency Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, and <sup>4</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, and <sup>4</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, and <sup>4</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, and <sup>4</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, Seoul National University Bundang Hospital, Seongnam, Seoul Nationa

**Background.** The impact of HIV infection on survival outcomes after in-hospital cardiopulmonary resuscitation (ICPR) remains controversial. This study aimed to investigate the impacts of HIV infection on both short-term and long-term outcomes after ICPR.

*Methods.* This nationwide, population-based cohort study used data taken from the South Korean National Health Insurance Service database. All adult (≥18 years old) patients who experienced ICPR between January 1, 2010, and December 31, 2019, were included.

**Results.** A total of 298 676 adult patients who underwent ICPR were initially included in the analysis. Among them, 586 (0.2%) patients were assigned to the patients with symptomatic HIV infection (PWH) group, while 298 090 (99.8%) patients were assigned to the control group. After 1:10 propensity score (PS) matching, 586 patients in the PWH group and 5845 patients in the control group were included in the analysis. Logistic regression analysis after PS matching showed that the PWH group had a 20% lower live discharge rate after ICPR compared with the control group (odds ratio, 0.80; 95% CI, 0.65–0.97; P = .024). However, Cox regression analysis after PS matching showed that the risks of 6-month survival (hazard ratio [HR], 1.01; 95% CI, 0.93–1.11; P = .768) and 1-year survival (HR, 1.02; 95% CI, 0.93–1.11; P = .702) were not significantly different between the PWH and control groups.

*Conclusions.* Although the PWH group showed lower live discharge rates compared with the control group after ICPR, long-term survival outcomes from 6 months and 1 year were not significantly different.

Keywords. critical care; hospital mortality; ICU outcomes; mortality; resuscitation.

AIDS was first reported in the 1980s [1], and HIV-related deaths, such as from acute infection syndrome and opportunistic infection, have subsequently been reported [2]. According to a report by the Joint United Nations Programme on HIV/AIDS [3], 37.7 million people globally were living with HIV in 2020, and 1.5 million people were newly infected with HIV in 2020. Moreover, 36.3 million people have died due to AIDS-related diseases since the start of the epidemic [3]. However, antiretroviral therapy (ART) has greatly improved life expectancy in people with HIV infection [4]. As ART for patients with AIDS is not curative, the HIV/AIDS

#### Open Forum Infectious Diseases®2022

pandemic is currently one of the most important global health challenges [5, 6].

A systematic review and meta-analysis of 313 006 adult patients reported that 46% and 31% of adult patients with AIDS were hospitalized due to AIDS-related diseases and bacterial infection, respectively [7]. During hospitalization, patients with AIDS might experience in-hospital cardiopulmonary resuscitation (ICPR) due to in-hospital cardiac arrest (IHCA). The outcomes of ICPR in patients with AIDS can be poor due to their immunosuppressed condition. Moreover, ICPR in patients with AIDS requires medical staff to take precautions in the form of gloves, googles, hand hygiene, and safety devices to prevent needlestick injuries [8, 9]; this need for additional protection measures may affect the outcomes of ICPR in patients with AIDS. In 1988, Raviglione et al. reported that 1 (2.3%) of 43 patients with AIDS who underwent ICPR were eventually discharged alive [10]. The live discharge rate after ICPR in patients with AIDS (2.3%) was relatively lower than that in other patients (15.2% in a literature review) [11]. However, a previous study by Raviglione et al. analyzed a relatively small sample size of 43 patients from July 1, 1986, to June 30, 1987 [10], and the conditions of patients with HIV infection were different in the

Received 18 January 2022; editorial decision 14 March 2022; accepted 17 March 2022; published online 18 March 2022.

Correspondence: In-Ae Song, MD, PhD, Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Gumi-ro, 173, Beon-gil, Bundang-gu, Seongnam, 13620, South Korea (songoficu@outlook.kr).

<sup>©</sup> The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/ licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://doi.org/10.1093/ofid/ofac144

1980s–1990s compared with the 2010s due to advances in ART [12]. Recently, Lavi Oud reported that, in the United States, short-term survival (defined as absence of hospital mortality or discharge to hospice) after ICPR was lower in patients with HIV infection than in patients without HIV infection [13]. However, Lavi Oud did not compare long-term survival outcomes after ICPR according to HIV infection.

Therefore, this study aimed to investigate the impacts of symptomatic HIV infection on both short-term and long-term outcomes after ICPR during hospitalization using a nationwide registration database in South Korea. We hypothesized that patients with symptomatic HIV infection (PWH) might have poorer outcomes after ICPR than other patients who have undergone ICPR.

## METHODS

## Study Design, Setting, and Ethical Concerns

This nationwide population-based cohort study followed the Strengthening of the Reporting of Observational Studies in Epidemiology guidelines [14]. The institutional review board (IRB) of the Seoul National University Bundang Hospital approved the study protocol (IRB number: X-2011-651-901), and the National Health Insurance Service (NHIS) permitted data sharing after approval of the study protocol (NHIS-2021-1-266). The requirement for informed consent was waived by the IRB of the Seoul National University Bundang Hospital because data analysis was performed retrospectively in an anonymized form.

## **Data Source**

The NHIS database was used in this study as it is a national health registration database. As the sole public insurance database system of South Korea, the NHIS database contains information regarding all disease diagnoses, drug prescriptions, and/or medical procedures. These registrations enabled patients to receive financial support from the government for treatment expenses. The International Statistical Classification of Disease and Related Health Problems, 10th Revision (ICD-10), codes were used to diagnose diseases.

## **Study Population**

We initially screened all CPR cases in South Korea using the prescription code of CPR between January 1, 2010, and December 31, 2019. Next, we excluded cases of CPR due to out-of-hospital cardiac arrest; all ICPR cases due to IHCA were selected for this study.

For any patient, all cases of ICPR per day were counted as 1 ICPR case. For example, if a patient received ICPR 3 times on a certain day during the study period, it was considered 1 ICPR case. This was because some patients experienced ICPR multiple times during a short duration in the same day and thus might bias the results. In our database, some patients experienced ICPR over 10 times in the same day. This could have caused a significant bias.

However, if a patient received ICPR 2 or more times on different days during the study period, only the first ICPR at the earliest date was included in this study. Therefore, if a patient received ICPR 2 times on January 3, 2010, and January 26, 2010, the first ICPR case on January 3, 2010, was considered, and the ICPR on January 26, 2010, was excluded from the final analysis. The homogeneity of the study population improved with this exclusion as a patient's physical condition might worsen at the later date of ICPR as opposed to the earlier date. Pediatric patients under 18 years old were also excluded from the analysis. Accurate death dates for all patients included in the study population were extracted and collected until April 30, 2021.

#### **Exposure Variable: Symptomatic HIV Infection**

ICD-10 codes B20–B24 were used for the extraction of PWH among the study population. The patients who were diagnosed with symptomatic HIV infection by ICD-10 codes within 1 year before the date of ICPR were defined as the PWH group, while the other patients were considered the control group in this study. In South Korea, patients with HIV infection should be registered in the NHIS database to receive financial coverage for their treatment. Specifically, ART for HIV infection and hospitalization for the treatment of complications due to HIV infection (such as opportunistic infections) are provided free of charge by the government in South Korea [15]. In general, standard precautions (gloves, googles, hand hygiene, and safety devices to prevent needlestick injuries) were emphasized to the medical staff when they performed ICPR in patients with AIDS.

## **End Points**

The primary end point of this study was live discharge after the ICPR. Secondary end points were survival at 6 months and 1 year after ICPR.

## Covariates

Age and sex were collected as the physical covariates. Employment status, residence, and household income level at the time of ICPR were collected to reflect the socioeconomic status of the study population. Self-employed patients were not considered employed, and residences were extracted using the ZIP codes of their homes at the time of hospital admission. National household income levels at the time of ICPR were registered in the NHIS database to determine insurance premiums for the Korean population, and the data were divided into 4 groups using the quartile ratio. The main diagnoses at the time of the ICPR were collected and divided into 4 groups according to ICD-10 codes: cardiovascular disease (I00–I99), respiratory disease (J00–J99), cancer (C00–D49), and others. The main diagnosis at the time of ICPR was determined by the NHIS after hospital discharge or death as the disease that required the greatest treatment or examination during the patient's hospitalization. The admitting departments at the time of ICPR were identified and classified into internal medicine (IM) and non-IM groups. The duration of the ICPR was classified into 1 of 5 groups: <15 minutes, 15-30 minutes, 30-45 minutes, 45-60 minutes, and >60 minutes. The hospitals where the ICPRs were performed during the study period were classified into 3 groups: tertiary general hospitals, general hospitals, and other hospitals. Moreover, hospitals were divided into 2 groups according to the total number of hospital beds, including those in intensive care units, namely <1000 beds and  $\geq$ 1000 beds. Annual ICPR case volumes were calculated based on the hospitals where the ICPRs were performed using the following formula: total ICPR cases among adult patients / 10 years. To reflect the comorbidity status of all patients, the Charlson comorbidity index (CCI) score was calculated using ICD-10 codes in the NHIS database registered no more than 1 year before the ICPR, as shown in Supplementary Table 1. Underlying disability at the time of ICPR was also extracted as a covariate. We recorded data on 15 types of disabilities, including physical disabilities, brain lesion disabilities, visual disturbances, hearing disturbances, speech disabilities, autism, intellectual disorder, mental disorder, renal disorder, heart diseases, respiratory disorders, hepatopathy, intestinal fistulae, urinary fistulae, and epilepsy. Additionally, each disability was assigned 1 of 6 grades based on severity; we grouped the severity grades into 2 groups (1-3, severe disability; and 4-6, mild to moderate disability).

#### **Statistical Analysis**

The clinicopathological characteristics of all patients are presented as mean values with standard deviations for continuous variables and numbers with percentages for categorical variables. We used propensity score (PS) matching to adjust for covariates between the PWH group and the control group. PS matching was performed using the nearest neighbor method with a 1:10 ratio without replacement and a caliper width of 0.15 [16]. Logistic regression analysis was performed to calculate PS as a logistic model, and all covariates were included in the PS model. We determined an adequate balance of all covariates using an absolute standardized difference (ASD) ≤0.1. Next, we performed logistic regression analysis to examine the odds of live discharge after ICPR in the PWH group compared with the control group in the PS-matched cohort. We also performed Cox regression analysis to examine the hazard ratios of 6-month and 1-year survival after ICPR in the PWH group compared with the control group in the PS-matched cohort. The results of the logistic regression analyses were presented as odds ratios (ORs) with 95% CIs, while those of Cox regression analyses were presented as hazard ratios (HRs) with 95% CIs. Moreover, the overall survival times after ICPR between the PWH group and the control group are presented using Kaplan-Meier curves,

and median survival times with 95% CIs in the 2 groups were compared using the log-rank test.

As a sensitivity analysis, we constructed a multivariable logistic model for live discharge after ICPR in the entire cohort to examine whether the results obtained in the PS-matched cohort were generalizable to the entire cohort. All covariates were included in the multivariable model for adjustment, except for CCI due to the multicollinearity with other underlying individual diseases that were used to calculate CCI. In addition, subgroup analysis of live discharge according to year of ICPR was performed using a multivariable logistic regression model, because health conditions in the PWH group may have improved from 2010 to 2019 due to development of ART [4]. Moreover, subgroup analyses according to CCI and age were performed, because comorbidity status and age might affect outcomes after ICPR in the PWH group. All patients were divided into 3 groups according to CCI (0-6, 7-10, and ≥11 points) and 4 groups according to age (18–40, 41–55, 56–70, and ≥71 years old). The Hosmer-Lemeshow test was used to confirm that the goodness of fit in the multivariate model was appropriate. There was no issue of multicollinearity between variables in the multivariable model using the criteria of variance inflation factors <2.0. R software (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses, and a P value <.05 was considered statistically significant.

## RESULTS

## **Study Population**

From January 1, 2010, to December 31, 2019, there were 478 836 CPR cases in South Korea. A total of 140 046 CPR cases due to out-of-hospital cardiac arrest were excluded from the analysis. Next, 31 122 cases in which a patient received ICPR more than once on different days during the study period and 8992 pediatric cases (under 18 years of age) were excluded from the final analysis. Finally, the remaining 298 676 adult patients who underwent ICPR were included in the analysis. Among them, 586 (0.2%) were in the PWH group, while 298 090 (99.8%) patients were in the control group. After 1:10 PS matching, 586 patients in the PWH group and 5845 patients in the control group were included in the analysis, as shown in Figure 1. The clinicopathologic characteristics of the PWH group and the control group before and after PS matching are presented in Table 1. All ASDs of covariates between the 2 groups were below 0.1, suggesting that the 2 groups had adequate balance through PS matching.

#### **Survival Analysis**

Table 2 shows the results of the survival analysis before and after PS matching. After PS matching, 24.2% (142 of 586) of the patients in the PWH group were alive after ICPR, while 28.6% (1674 of 5845) of the patients in the control group were also alive



Figure 1. Flowchart depicting patient selection process. Abbreviations: CPR, cardiopulmonary resuscitation; OHCA, out-of-hospital cardiac arrest; PSM, propensity score matching; PWH, patients with symptomatic HIV infection.

after ICPR. In the logistic regression analysis, the PWH group showed a 20% lower live discharge rate after ICPR than the control group (OR, 0.80; 95% CI, 0.65–0.97; *P* = .024). However, the risks associated with the 6-month survival rate (HR, 1.01; 95% CI, 0.93–1.11; *P* = .768) and 1-year survival rate (HR, 1.02; 95%) CI, 0.93-1.11; P = .702) were not significantly different between the 2 groups. Figure 2 shows the overall survival time after ICPR in the 2 groups using Kaplan-Meier curves in the PS-matched cohort. The median survival time after ICPR in the PWH group was 8 days (95% CI, 6.7-9.7), while that in the control group was 6 days (95% CI, 5.5–6.6; *P* = .929). Table 3 shows the results of the multivariable logistic regression model for live discharge after ICPR among the entire cohort. The PWH group showed a 22% lower live discharge rate after ICPR than the control group (OR, 0.78; 95% CI, 0.64–0.95; *P* = .012). Supplementary Tables 2, 3, and 4 show the results of subgroup analyses according to year of ICPR, age, and CCI. All subgroups showed no statistically significant differing trends in live discharge between the PWH group and the control group (all P > .05).

## DISCUSSION

In this study, using a nationwide database in South Korea, we showed that PWH were associated with a lower live discharge rate after ICPR than the control group. However, long-term survival outcomes at 6 months and 1 year after ICPR did not differ between the PWH group and the control group. These associations were applied to both the PS-matched cohort and the entire cohort using multivariable adjustment. This is the first study to show both short-term and long-term outcomes after ICPR in PWH compared with the control group.

A similar study by Lavi Oud reported that the incidence of ICPR was similar among those hospitalized with and without HIV infection; however, HIV-infected patients have been shown to have lower short-term survival rates in the United States [13]. In terms of short-term survival outcomes, Oud reported findings similar to those of our study. Oud analyzed 437 and 54 135 patients with and without HIV, respectively, who experienced ICPR during hospitalization in the United States [13], while we analyzed 586 and 298 090 subjects in the PWH group and the control group, respectively, who experienced ICPR during hospitalization in South Korea. The findings from our study and those of Lavi Oud contradict those of a previous study by Mongardon et al., which reported that ICU mortality after cardiac arrest was not significantly affected by HIV infection among 99 patients [17]. In addition to the study by Lavi Oud, our study analyzed a large sample size using a national registration database in South Korea, which might be more robust than the study by Mongardon et al. [17]. Most importantly, we first reported that although short-term outcomes after ICPR might be worse in patients with AIDS, long-term survival outcomes after ICPR were not significantly affected by HIV infection.

## Table 1. Clinicopathologic Characteristics of the PWH and Control Groups Before and After PS Matching

PPHH metabolCannolPPHH metabolCannolPPHH metabolCannolASDAge62.7 (15.8)69.9 (16.2)0.46362.7 (15.8)0.009Sex. male12.3 (12.2)17.9 (7) (10.1)0.23342.2 (12.2)47.15 (4.1)0.001Rendmag abol11.8 (10.1)11.8 (10.1)0.13342.15 (12.2)47.15 (4.1)0.001Rendmag21.3 (13.3)11.9 (10.1)0.13327.15 (4.2)27.15 (4.1)0.011Rundmag21.3 (13.3)11.9 (14.1)21.9 (24.1)21.9 (24.1)21.9 (24.1)0.000Rundmag21.9 (14.1)9.0 (15.5)0.02227.16 (16.1)0.0010.000C211.0 (14.1)0.13341.9 (15.5)0.02211.9 (24.1)12.9 (24.2)0.001C311.0 (14.1)0.13441.9 (15.6)0.02212.9 (24.2)0.001C412.8 (24.2)12.9 (24.1)12.9 (24.2)0.0010.03812.4 (12.1)12.9 (24.2)0.001C412.8 (14.1)10.13 (14.1)0.13312.4 (14.1)0.0220.0020.002C412.8 (14.1)12.9 (24.1)12.9 (24.1)0.00112.9 (24.1)0.001Uhirkowon18.1 (14.1)10.13 (14.1)0.13312.4 (14.1)0.0220.002Candmase (1CP)10.7 (11.10 (11.1)0.13049.1 (14.1)0.03212.4 (14.1)0.022Candmase (1CP)10.7 (11.10 (11.1)0.13049.1 (15.1)0.0020.001Chird absorment <th></th> <th>Before I</th> <th>PS Matching</th> <th></th> <th colspan="2">After PS Matching</th> <th></th>		Before I	PS Matching		After PS Matching		
Variable         (in = 980)         (in = 280 00)         ASD         (in = 980)         (in = 981)         ASD           Sex, male         423 172.2)         (ir 9971.401.4)         0.275         423 172.2)         257.1141.4         0.019           Sex, male         423 172.2)         (ir 9971.401.4)         0.275         423 172.2)         257.1141.4         0.019           Ream area         27.914.61         128 280 161.2)         0.163         253 (43.2)         257.1141.4         0.019           Ream area         27.914.61         129 374.122         27.914.75.0         0.010           Howard income level at ICPR         219 167.41         93 553 131.41         219 167.41         219 167.41         219 167.41         219 167.41         219 167.01         0.000           G3         121 171 183         445 171.51         0.042         121 172.12         122 02 02.01         0.010           Unknown         61 141         61 21 171.01         0.237         121 172.12         122 02 02.01         0.010           Unknown         61 197.11         50 151.01         151 051.01         151 051.01         151 051.01         151 051.01         151 051.01         151 051.01         151 051.01         151 051.01         151 051.01         151 051.01		PWH	Control		PWH	Control	
App         BF 8 (15.2)         0.4K1         DP 7 (15.8)         DD 7 (15.8) <thd (15.8)<="" 7="" th="">         DD 7 (15.8)         DD 7 (15.</thd>	Variable	(n = 586)	(n = 298 090)	ASD	(n = 586)	(n = 5845)	ASD
See, marke         423 (72.2)         178 871 (80.4)         0.273         423 172.2)         471 77.14)         0.016           Paradamora al CPR          223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         223 46.6)         203 45.2)         223 46.6)         233 45.2.4)         0.000           Household innome level at CPR          219 (37.4)         93 559 131.4)         219 (37.4)         219 (37.4)         219 (37.4)         200 00.00           G.2         107 (18.3)         46 119 115 18         0.072         107 118.3)         1006 11.00         228 (19.0)         0.010           G.3         124 (12.1)         0.141 18         0.012         11.00 02         0.010         0.011         0.011         0.011         0.011         0.011         0.011         0.0	Age	62.7 (15.6)	69.9 (15.2)	0.463	62.7 (15.6)	62.7 (15.6)	0.009
Haying a loo at ICPR         253 (H3.2)         0.103         253 (H3.2)         257 (H4.0)         0.006           Intenances         273 (46.6)         128 784 (43.2)         273 (46.6)         273 (46.6)         2097 (63.0)         0.000           House area         313 (63.4)         109 306 (63.6)         0.008         313 (63.4)         2097 (63.0)         0.000           Household income level at ICPR          10         0.008         312 (63.4)         2097 (63.0)         0.000           G2         107 (118.3)         46 119 155         0.072         102 (118.0)         1056 (118.2)         0.000          G3         (124 (21.2)         46 150 (0.227)         128 (21.0)         0.045         81 (4.0)         0.001           G4         128 (21.0)         0.045         81 (4.0)         83 (26.6)         0.077           Unknown         81 (4.1)         50 (13.0)         101 (25.8)         113 0.0 (33.2)         26.6 (1.0)         0.000           Cancerses at LCPH          201 (65.1)         107 (71.10 (1.0)         10.10         48 (9.2)         0.001           Cancerses at LCPH          201 (65.1)         107 (13.1)         0.402         201 (65.1)         201 (65.1)         201 (65.1)         201 (65.1)	Sex, male	423 (72.2)	179 971 (60.4)	0.263	423 (72.2)	4175 (71.4)	0.017
Peademone at ICPR         273 (46.0         1273 (46.0         273 (46.0	Having a job at ICPR	253 (43.2)	152 800 (51.3)	0.163	253 (43.2)	2571 (44.0)	0.016
Uhman area         273 (46.6) <th274 (47.0)<="" th="">         273 (46.6)         273 (46.</th274>	Residence at ICPR						
Bura iaraa         913 (53.4)         103 305 (56.8)         0.008         913 (53.4)         2097 (53.0)         0.00           Di Rossehil income level it CPR         219 (37.4)         210 (37.4)         2	Urban area	273 (46.6)	128 784 (43.2)		273 (46.6)	2748 (47.0)	
Heashbol neome level at ICFR 01 flowesh 02 10 (invest) 12 2 10 (37.4) 915 (56.1) 0.072 107 (18.3) 9105 (18.2) 40.000 03 124 (21.2) 915 60.138 (1) 0.072 107 (18.3) 9105 (18.2) 40.000 04 128 (21.8) 94298 (31.6) 0.227 128 (21.8) 1320 (22.6) 0.007 Unknown 6 (14) 5612 (19) 0.045 8 (14) 1320 (22.6) 0.007 Unknown 6 (14) 5612 (19) 0.045 8 (14) 1320 (22.6) 0.007 Carcinoaccular disease 151 (25.8) 115 0.08 (38.6) 151 (25.8) (55.3) 26.6) Carcinoaccular disease 156 (8) 41 30 014 (1) 0.139 56 (9) 555 (26.6) 0.000 Carcar 4 48 (8.2) 33 450 (11.2) 0.110 48 (8.2) 1228 (56.3) 0.000 Carcar 4 (8.6) 1007 31 (8.1) 0.033 29 (56.3) 1228 (56.3) 0.000 Carcar 4 (8.6) 1007 31 (8.1) 0.033 29 (56.3) 1228 (56.3) 0.000 Carcar 100 (10.6) 106 378 (55.8) 0.011 (12.2) 0.022 (12.2) 0.010 Carcino 110PR	Rural area	313 (53.4)	169 306 (56.8)	0.068	313 (53.4)	3097 (53.0)	0.010
C1 (0x+est)         219 (37.4)         93 569 (31.4)         219 (37.4)         216 (37.4)         216 (37.6)         -	Household income level at ICPR						
Q2         107/18.3         46 19/15.9         0.072         107/18.3         1065/18.2         -0.000           Q3         124 (212)         560/410.6         0.038         124 (212)         122 (212)         122 (212)         122 (212)         122 (212)         122 (212)         123 (212)         123 (212)         123 (212)         123 (212)         0.007           Cardiovascuar disease         151 (25.8)         115 100 (38.6)         151 (25.8)         155 (26.6)         156 (26.6)           Cardiovascuar disease         151 (25.8)         115 (25.8)         165 (26.6)         0.009           Cardiovascuar disease         151 (25.8)         100 (08.4)         123 (46.1)         0.009           Cardiovascuar disease         151 (25.8)         100 (08.4)         123 (46.1)         0.009           Cardiovascuar disease         151 (25.8)         100 (08.4)         123 (46.1)         0.009           Admitting digartment         100 (08.4)         123 (46.1)         100 (08.4)         123 (46.1)         100 (08.4)         124 (47.6)         0.019           Outrish         152 (28.14.0)         135 407 (45.4)         0.217         188 (14.1)         100 (28.1)         0.002           Outrish         153 (40.7)         0.221         188 (48.1) <t< td=""><td>Q1 (lowest)</td><td>219 (37.4)</td><td>93 559 (31.4)</td><td></td><td>219 (37.4)</td><td>2159 (36.9)</td><td></td></t<>	Q1 (lowest)	219 (37.4)	93 559 (31.4)		219 (37.4)	2159 (36.9)	
G3         124 (21,2)         95 804 (19,6)         0.038         124 (21,2)         1220 (20,9)         0.007           Unknown         8 (1,4)         5612 (19,9)         0.042 928 (13,6)         0.237         1228 (21,8)         1320 (22,6)         0.017           Cardiovascular disease         151 (25,8)         115 008 (38,6)         151 (25,8)         1563 (26,6)         0.007           Cardiovascular disease         151 (25,8)         115 008 (38,6)         0.109         448 (8,2)         3344 (65,6)         0.009           Chrier         328 (66,1)         107 731 (36,1)         0.403         329 (61,1)         3244 (65,6)         0.009           Admitting dispartment         155 (31,4)         137 712 (42,1)         0.211         156 (31,4)         199 (32,6)         0.007           Nor-IM         156 (31,4)         163 376 (74,54)         256 (44,0)         260 (44,6)         106 (27,7)         126 (28,1)         138 (28,2)         138 (28,2)         138 (28,2)         148 (28,1)         33 (16,7)         0.021           Set 44,0         135 407 (45,4)         256 (44,0)         102 (44,3)         26 (42,0)         26 (41,1)         26 (42,0)         26 (41,1)         26 (42,0)         26 (41,1)         0.002         16 (45,1)         0.002         16 (45,1) <td>Q2</td> <td>107 (18.3)</td> <td>46 119 (15.5)</td> <td>0.072</td> <td>107 (18.3)</td> <td>1065 (18.2)</td> <td>&lt;0.001</td>	Q2	107 (18.3)	46 119 (15.5)	0.072	107 (18.3)	1065 (18.2)	<0.001
G4         129 (21.9)         94 296 (31.6)         0.237         128 (21.9)         120 (22.6)         0.017           Main diagnosis at ICPR	Q3	124 (21.2)	58 504 (19.6)	0.038	124 (21.2)	1220 (20.9)	0.006
Unknown 8 (1.4) 6512 (1.9) 0.045 8 (1.4) 8 (1.1) 0.002 Main diagnosis at ICPR Cardiovsscular disease 151 (25.8) 115 (08.38.6) 151 (25.8) 1553 (25.6) Respiratory disease 58 (9.9) 41 901 (14.1) 0.133 58 (9.9) 565 (9.7) 0.003 Cancer 48 (8.2) 33 450 (11.2) 0.110 48 (8.2) 479 (8.2) 0.001 Other 329 (96.1) 107 73 (36.1) 0.003 329 (96.1) 2248 (96.6) 0.009 Admiting department M 401 (88.4) 166 378 (55.8) 401 (46.4) 3944 (65.5) Non-M 185 (31.4) 131 712 (44.2) 0.271 185 (31.4) 1901 (32.5) 0.019 Duration of ICPR 256 (44.0) 135 407 (45.4) 256 (44.0) 2609 (44.6) 15-30 192 (02.8) 86 342 (29.0) 0.081 192 (32.8) 1995 (32.4) 0.007 30-45 70 (13.0) 40 772 (13.7) 0.021 76 (13.0) 771 (12.2) 0.022 37-45 70 (13.0) 40 772 (13.7) 0.021 76 (13.0) 771 (12.2) 0.022 37-45 70 (13.0) 40 772 (13.7) 0.021 76 (13.0) 771 (12.2) 0.022 37-60 26 (4.4) 16 378 (5.5) 0.061 28 (4.4) 294 (5.0) 0.082 37-60 26 (4.4) 16 378 (5.5) 0.061 28 (4.4) 294 (5.0) 0.028 37-60 26 (4.4) 16 378 (5.5) 0.061 28 (4.4) 294 (5.0) 0.028 37-60 26 (4.4) 170 244 (37.0) 244 (32.0) 4248 (41.9) Tertary general hospital 293 (50.0) 153 027 (51.3) 0.027 293 (50.0) 248 (5.6) 0.011 Tertary general hospital 293 (50.0) 153 027 (51.3) 0.027 293 (50.0) 248 (5.6) 0.011 194 carbodie (10.7) 5000 10 (61.8) 1 45.30 (75.1) 0.021 194 (23.0) 4248 (41.7) 5100 10 (10.8) 11 15.0 (11.5) 74 720 (25.1) 91 (15.5) 91 (15.5) 57-14 224 (24.1) 75 96 (25.5) 0.321 242 (24.1) 3 236 (40.4) 0.015 194-270 11 91 (20.3) 72 794 (24.4) 0.012 119 (20.3) 108 (20.0) 0.028 5100 106 (10.7) 194-270 11 91 (20.3) 72 794 (24.4) 0.012 119 (20.3) 108 (20.0) 0.028 5100 106 (12.8) 49 (10.0) 21 103 (12.2.9) 1000 (12.2.9) 0.002 5100 106 (12.8) 40.10 119 (20.3) 102 (21.9) 0.020 5100 106 (12.8) 40.10 119 (20.3) 102 (22.0) 0.020 5100 106 (12.8) 40.10 119 (20.3) 102 (22.0) 0.020 5100 100 (12.9) 110 (10.1) 110 (20.0) 110 (22.9) 110 (20.0) 0.022 5000 100 (12.8) 110 (0.102 119 (22.9) 110 (0.022 5000 100 (12.8) 110 (0.103 110 (22.9) 110 (0.113 112.2.9) 1100 (12.2.9) 0.002 5000 100 (12.8) 110 (0.103 110 (22.9	Q4	128 (21.8)	94 296 (31.6)	0.237	128 (21.8)	1320 (22.6)	0.017
Main disposis at ICPR Cardiovascular disease 101 (25.8) 115 008 (38.6) 115 1(25.8) 105 2(25.6) 105 2(2	Unknown	8 (1.4)	5612 (1.9)	0.045	8 (1.4)	81 (1.4)	0.002
Cardiovascular disease         161 (25.8)         115 008 (38.6)         151 (25.8)         155 3 (25.6)           Despiratory disease         58 (9.9)         41 901 (14.1)         0.10         48 (9.2)         429 (0.0)           Other         329 (66.1)         107 731 (38.1)         0.403         3248 (65.6)         0.009           Almiting department         100         48 (9.2)         0.271 (38.1)         0.403         3248 (65.6)         0.009           Almiting department         258 (44.0)         105 (37.6)         401 (66.4)         9344 (67.5)         0.019           Duration of ICPR         258 (44.0)         135 407 (45.4)         0.221         76 (13.0)         269 (44.6)         0.007           30-45         76 (13.0)         0.072 (13.7)         0.021         76 (13.0)         0.007         24 (58)         100 007           30-45         76 (13.0)         0.072 (13.7)         0.021         76 (13.0)         0.027         29 (50.0)         26 (4.4)         0.027         30 (4.1)         0.028           Type of hospital         246 (42.0)         112 044 (376)         246 (42.0)         2446 (41.0)         0.018           Terking eneral hospital         246 (42.0)         112 044 (376)         0.027         29 (60.0)         0.006<	Main diagnosis at ICPR						
Respiratory disease         58 (0.9)         41 90 (14.1)         0.139         58 (0.9)         66 (9.7)         0.009           Chner         329 (56.1)         107 731 (36.1)         0.403         329 (56.1)         324 (55.6)         0.009           Admitting department	Cardiovascular disease	151 (25.8)	115 008 (38.6)		151 (25.8)	1553 (26.6)	
Cancer         48 (6.2)         33 480 (11.2)         0.110         48 (6.2)         479 (8.2)         0.001           Other         329 (6.1)         107 73 (8.1)         0.403         329 (6.1)         3248 (5.6)         0.009           Admitting department         107 73 (8.1)         0.403         3249 (6.5)         0.016         3944 (62.5)         0.019           Duration of ICPR         256 (44.0)         135 407 (42.2)         0.271         185 (31.4)         199 (132.5)         0.007           30-45         76 (13.0)         40 772 (13.7)         0.021         76 (13.0)         716 (12.2)         0.022           45-60         34 (5.6)         191 93 (6.4)         0.027         78 (5.3)         331 (5.7)         0.005           560         26 (4.4)         16 376 (5.5)         0.051         26 (4.4)         294 (5.0)         0.028           Type of hospital         273 (50.0)         153 027 (51.3)         0.027         236 (50.0)         296 (50.6)         0.011           Other hospital         273 (50.0)         153 027 (51.3)         0.027         236 (50.0)         296 (50.6)         0.011           Other hospital         273 (80.0)         153 027 (51.3)         0.027         236 (40.0)         0.016	Respiratory disease	58 (9.9)	41 901 (14.1)	0.139	58 (9.9)	565 (9.7)	0.009
Other         329 (6.1)         107 73 (6.1)         0.003         329 (6.1)         328 (6.5)         0.009           Miniting deartment         MA         401 (68.4)         166 378 (55.6)         401 (68.4)         394 (67.5)         0.019           Duration of ICPR         258 (40.0)         135 407 (45.4)         258 (40.0)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.4)         260 (41.6)         155 407 (45.5)         0.021         76 (13.6)         76 (13.6)         76 (13.6)         76 (13.6)         76 (13.6)         0.027         246 (42.0)         248 (42.0)         0.028         168 51 (24.6)         0.027         246 (42.0)         248 (41.7)         0.005         301 (11.1)         0.112         47 (6.0)         441 (7.5)         0.011           Other hospital         293 (60.0)         153 027 (61.3)         0.027         293 (60.0)         296 (60.6)         0.011           Other hospital         47 (6.0)         430 (91.9)         252 704 (84.8)         480 (91.9)         476 (81.7)         1016 (8.1)	Cancer	48 (8.2)	33 450 (11.2)	0.110	48 (8.2)	479 (8.2)	0.001
Admitting department IM 401 (68.4) 401 (68.4) 166 378 (55.8) 401 (68.4) 3944 (67.5) Non-IM 186 (31.4) 131 712 (44.2) 0.271 185 (31.4) 1901 (32.5) 0.019 Duration of ICPR 256 (44.0) 135 407 (45.4) 258 (44.0) 2509 (44.6) 15-30 122 (32.8) 86 342 (23.0) 0.061 192 (32.8) 1995 (32.4) 0.007 30-45 76 (13.0) 40 772 (13.7) 0.021 76 (13.0) 716 (12.2) 0.022 45-60 34 (5.8) 19 193 (6.4) 0.027 34 (5.8) 331 (5.7) 0.005 >50 26 (4.4) 16 376 (5.5) 0.051 26 (4.4) 234 (5.0) 0.028 Triary general hospital 246 (42.0) 112 044 (37.6) 246 (42.0) 2448 (41.9) General hospital 233 (50.0) 150 027 (51.3) 0.027 233 (50.0) 2395 (50.0) 0.018 Total hospital 247 (8.0) 33 019 (11.1) 0.112 47 (8.0) 444 (17.5) 0.018 Total hospital 47 (8.0) 33 019 (11.1) 0.112 47 (8.0) 444 (17.5) 0.018 Total hospital 47 (8.0) 33 019 (11.1) 0.112 47 (8.0) 444 (17.5) 0.018 Total hospital 47 (8.0) 33 019 (11.1) 0.112 47 (8.0) 444 (17.5) 0.018 Total hospital 47 (8.0) 33 019 (11.1) 0.112 47 (8.0) 444 (17.5) 0.018 Total hospital 47 (8.0) 33 019 (11.1) 0.112 47 (8.0) 444 (17.5) 0.018 Total hospital 40 (81.9) 25 2704 (44.8) 0.74 106 (18.1) 1066 (18.7) 21000 106 (18.1) 45 386 (15.2) 0.074 106 (18.1) 1066 (18.7) 21000 106 (18.1) 3 78 965 (25.5) 0.321 242 (41.3) 2364 (40.4) 0.015 194-276 119 (20.3) 72 794 (24.4) 0.102 119 (20.3) 1168 (20.0) 0.002 277 134 (22.9) 746 (11.25,0) 0.051 134 (22.9) 1402 (24.0) 0.002 177 134 (22.9) 746 (11.25,0) 0.051 134 (22.9) 1402 (24.0) 0.002 177 134 (22.9) 746 (11.25,0) 0.051 134 (22.9) 1402 (24.0) 0.002 177 134 (22.9) 746 (11.25,0) 0.051 134 (22.9) 1402 (24.0) 0.002 177 134 (22.9) 746 (11.26,0) 0.051 134 (22.9) 1402 (24.0) 0.002 178 (27.1) 17347 (13.0) 0.28 (6.9) (4.4) (6.9 (4.1)) 0.002 192 (22.0) 0.007 CCl at (CPR 6.9 (4.14) 6.0 (3.9) 0.208 (6.9) (4.4) 6.9 (4.1) 0.002 193 (22.2) 0.002 Congestive heart failure 250 (42.7) 117 347 (33.4) 0.066 250 (42.7) 2.249 (43.0) 0.005 277 2476 (42.8) 0.005 247 (32.0) 106 (18.1) 106 (18.1) 0.001 (18.2) 0.005 270 (21.6) (CPR 6.9 (4.4) 6.0 (3.9) 0.002 (33.8) (4.9) 0.000 Mycardial i	Other	329 (56.1)	107 731 (36.1)	0.403	329 (56.1)	3248 (55.6)	0.009
IM         401 (66.4)         166 378 (55.8)         401 (68.4)         3944 (67.5)           Non-IM         156 (31.4)         131 712 (44.2)         0.271         115 (31.4)         1901 (32.5)         0.019           Duration of ICPR         256 (44.0)         135 407 (45.4)         258 (44.0)         2669 (44.0)         2000 (40.0)           30-45         76 (13.0)         40 772 (13.7)         0.021         76 (13.0)         716 (12.2)         0.022           45-60         34 (5.8)         1913 (6.4)         0.027         24 (5.8)         331 (5.7)         0.028           560         26 (42.0)         112 044 (27.6)         246 (42.0)         2446 (4.19)         General hospital         233 (50.0)         156 027 (51.3)         0.027         293 (50.0)         2266 (60.6)         0.011           Other hospital         246 (42.0)         112 044 (27.6)         246 (42.0)         2468 (41.9)          60.011           Other hospital         47 (8.0)         33 019 (11.1)         0.112         47 (8.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)         2469 (7.0)	Admitting department						
Non-M         185 (31.4)         191 (12, 12, 14, 12)         0.271         1185 (31.4)         1901 (32, 5)         0.019           Duration of ICPR         258 (44.0)         135 407 (45.4)         258 (44.0)         2609 (44.6)         0.007           15-30         192 (32.8)         663 42 (29.0)         0.061         192 (32.8)         1999 (32.4)         0.007           45-60         34 (5.8)         19 133 (6.4)         0.027         34 (5.8)         331 (5.7)         0.005           50         26 (4.4)         16 376 (5.5)         0.051         246 (42.0)         2448 (41.9)         120 (42.8)         0.007           Tertiary general hospital         246 (42.0)         112 044 (37.6)         246 (42.0)         2448 (41.9)         0.019           Tertiary general hospital         47 (8.0)         133 027 (51.3)         0.027         239 (50.0)         2956 (50.6)         0.011           Other hospital         47 (8.0)         143 (37.6)         246 (42.0)         244 (1.5)         0.018           Total hospital         47 (8.0)         193 (15.1)         0.019         477.6 (8.1)         0.016           Total hospital         47 (8.0)         242 (41.3)         756 (52.5)         0.321 224 (41.3)         236 (40.4)         0.015      <	IM	401 (68.4)	166 378 (55.8)		401 (68.4)	3944 (67.5)	
Duration of ICPH         258 (44.0)         135 407 (45.4)         258 (44.0)         2609 (44.6)           15-30         192 (32.8)         86 342 (29.0)         0.081         192 (32.8)         1895 (32.4)         0.007           30-45         76 (13.0)         40 772 (13.7)         0.027         34 (5.8)         103 (0.007)         36 (4.8)         103 (0.07)         34 (5.8)         10.005         >60         26 (4.4)         16 376 (5.5)         0.051         26 (4.4)         294 (5.0)         0.028           Type of hospital         746 (12.0)         112 044 (37.6)         246 (42.0)         2448 (41.9)         General hospital         246 (42.0)         124 48 (1.9)         0.027         293 (50.0)         2956 (50.6)         0.011           Other hospital         246 (42.0)         153 027 (51.3)         0.027         293 (50.0)         2956 (50.6)         0.011           Other hospital         476 (8)         33 019 (11.1)         0.112         418.0)         441 (75)         0.018           Total hospital bod number         7         74.80         30.9 (11.8)         480 (81.9)         4776 (81.7)           21000         108 (18.9)         252 704 (84.8)         480 (81.9)         478 (81.7)         2100           2000         106 (18.1)	Non-IM	185 (31.4)	131 712 (44.2)	0.271	185 (31.4)	1901 (32.5)	0.019
15-30         192 (12.8)         86 342 (22.0)         0.081         192 (32.8)         1895 (32.4)         0.007           30-45         76 (13.0)         40 772 (13.7)         0.021         76 (13.0)         716 (12.2)         0.022           45-60         34 (5.8)         19 193 (6.4)         0.027         34 (5.8)         331 (5.7)         0.002           5-60         26 (4.4)         16 376 (5.5)         0.051         26 (4.4)         244 (4.0)         0.022           Forting general hospital         246 (42.0)         112 0.44 (37.6)         246 (42.0)         2448 (41.9)         General hospital         293 (50.0)         153 027 (51.3)         0.027         239 (50.0)         2956 (50.6)         0.011           Other hospital         47 (8.0)         430 (81.9)         252 704 (84.8)         440 (81.9)         441 (75)         0.018           Total hospital bed number           450 (81.9)         4776 (81.7)          106 (18.1)         105 (11.3)         0.006         30 (91.9)         777 (82.0)         91 (15.5)         911 (15.6)         91 (15.5)         911 (15.6)         91 (15.5)         911 (15.6)         91 (15.5)         911 (15.6)         91 (15.5)         911 (15.6)         91 (15.5)         911 (15.6)         911 (15.6)	Duration of ICPR						
115-30       119 (32.8)       B6 342 (29.0)       0.081       192 (22.8)       11895 (32.4)       0.0007         30-45       76 (13.0)       0.772 (13.7)       0.021       76 (13.0)       776 (12.0)       0.022         45-60       24 (5.8)       19 193 (6.4)       0.027       34 (5.8)       331 (5.7)       0.005         >60       26 (4.4)       16 376 (5.5)       0.051       26 (4.4)       294 (5.0)       0.028         Tertiary general hospital       246 (42.0)       112 044 (376)       246 (42.0)       246 (42.0)       293 (50.0)       295 (50.6)       0.011         Other hospital       293 (50.0)       153 027 (51.3)       0.027       293 (50.0)       295 (50.6)       0.011         Other hospital bed number       470 (8.0)       33 019 (11.1)       0.112       47 (8.0)       440 (81.9)       4776 (81.7)         > 1000       106 (18.1)       453 66 (15.2)       0.321       242 (41.3)       2364 (40.4)       0.015         194-276       19 (15.5)       74 720 (25.1)       91 (15.5)       911 (15.6)       111 (15.6)         277       134 (22.9)       74 61 (12.6)       0.021       119 (20.3)       1168 (20.0)       0.002         277       134 (22.9)       74 (12.6) <td< td=""><td>15.00</td><td>258 (44.0)</td><td>135 407 (45.4)</td><td>0.004</td><td>258 (44.0)</td><td>2609 (44.6)</td><td>0.007</td></td<>	15.00	258 (44.0)	135 407 (45.4)	0.004	258 (44.0)	2609 (44.6)	0.007
30-45       76 (13.0)       40 7/2 (13.7)       0.021       76 (13.0)       716 (12.2)       0.022         45-60       34 (5.8)       19 193 (6.4)       0.027       34 (5.8)       331 (5.7)       0.005         >60       26 (4.4)       16 376 (5.5)       0.051       26 (4.4)       294 (5.0)       0.028         Tertiary general hospital       246 (42.0)       112 044 (37.6)       246 (42.0)       248 (41.9)       General hospital       47 (8.0)       33 019 (11.1)       0.112       47 (8.0)       441 (7.5)       0.018         Total hospital       47 (8.0)       33 019 (11.1)       0.112       47 (8.0)       441 (7.5)       0.018         Total hospital       47 (8.0)       126 (14.8)       450 (81.9)       4776 (81.7)           0.00       106 (18.1)       45 366 (15.2)       0.074       106 (18.1)       1069 (18.3)       0.006         Annual case volume of ICPR       -       -       -       -       -       -       -       -       -       -       -       -       0.026       0.011       -       -       -       -       0.026       -       -       -       -       -       -       -       -       -       -       -<	15–30	192 (32.8)	86 342 (29.0)	0.081	192 (32.8)	1895 (32.4)	0.007
4b-B0         34 (5.8)         19 193 (6.4)         0.027         34 (5.8)         331 (5.7)         0.00b           >60         26 (4.4)         16 376 (5.5)         0.021         26 (4.4)         294 (5.0)         0.028           Tertiary general hospital         246 (42.0)         112 044 (37.6)         246 (42.0)         246 (42.0)         249 (5.0)         0.021           General hospital         233 (50.0)         153 027 (51.3)         0.027         293 (50.0)         246 (42.0)         441 (7.5)         0.011           Other hospital         47 (8.0)         33 019 (11.1)         0.112         47 (8.0)         441 (7.5)         0.018           Total hospital bed number         -         -         0.024         106 (18.1)         1069 (18.3)         0.006           Annual case volume of ICPR         -         -         0.021         119 (20.3)         72 794 (24.4)         0.102         119 (20.0)         0.009           277         134 (22.9)         74 611 (25.0)         0.051         134 (22.9)         1402 (24.0)         0.022         0.007           194-276         119 (20.3)         72 794 (24.4)         0.102         119 (20.3)         0.208         0.94 (4.1)         6.9 (4.1)         0.002           Severe	30-45	76 (13.0)	40 772 (13.7)	0.021	76 (13.0)	716 (12.2)	0.022
>b0         2 b (4.4)         16 3 / b (5.b)         0.05         2 b (24)         2 94 (b.0)         0.028           Type of hospital         Entriary general hospital         246 (42.0)         112 044 (37.6)         246 (42.0)         2448 (41.9)           General hospital         233 (50.0)         155 027 (61.3)         0.027         233 (50.0)         2956 (50.6)         0.011           Other hospital         47 (8.0)         33 019 (11.1)         0.12         47 (8.0)         441 (75)         0.018           Total         hospital         47 (8.0)         160 (18.1)         453 06 (15.2)         0.074         106 (18.1)         1069 (18.3)         0.006           Annual case volume of ICPR         0.074         101 (15.5)         911 (15.6)         911 (15.6)         911 (15.6)         0.021         1168 (20.0)         0.006           7.73         134 (22.9)         74 611 (25.0)         0.051         134 (22.9)         1402 (24.0)         0.022           Mid to moderate         61 (10.4)         35 235 (11.8)         0.046         61 (10.4)         607 (10.4)         0.002           Coractic disease         12 (92.0)         51 55 91 (73)         0.114         12 92 (2.0)         1300 (22.2)         0.007           Coractic disease <t< td=""><td>45-60</td><td>34 (5.8)</td><td>19 193 (6.4)</td><td>0.027</td><td>34 (5.8)</td><td>331 (5.7)</td><td>0.005</td></t<>	45-60	34 (5.8)	19 193 (6.4)	0.027	34 (5.8)	331 (5.7)	0.005
Type or nospital         246 (42.0)         112 044 (37.6)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         246 (42.0)         2956 (50.6)         0.011           Other hospital         47 (8.0)         47 (8.0)         47 (8.0)         441 (75)         0.018           Total hospital         47 (8.0)         480 (81.9)         252 704 (64.8)         480 (81.9)         4776 (81.7)           ≥1000         106 (18.1)         45 386 (15.2)         0.074         106 (18.1)         1069 (18.3)         0.006           Annual case volume of ICPR         0         56         91 (15.5)         74 720 (25.1)         91 (15.5)         91 (15.5)         116 (20.0)         0.009           277         134 (22.9)         74 611 (25.0)         0.51         134 (22.9)         1402 (24.0)         0.002           Severe         129 (22.0)         51 559 (17.3)         0.114         129 (22.0)         0.007           Clare flow disability         Mid to moderate         61 (10.4)         6.0 (3.9)         0.208         6.9 (4.4)         6.9 (4.1)         0.002	>60	26 (4.4)	16 3 /6 (5.5)	0.051	26 (4.4)	294 (5.0)	0.028
Interviting general hospital         246 (42.0)         112 044 (37.6)         246 (42.0)         2448 (41.9)           General hospital         293 (50.0)         153 027 (51.3)         0.027         293 (50.0)         246 (60.6)         0.011           Other hospital         47 (8.0)         33 019 (11.1)         0.112         47 (8.0)         441 (75)         0.018           Total hospital bed number           480 (81.9)         252 704 (84.8)         480 (81.9)         4776 (81.7)           ≥1000         106 (18.1)         45 386 (15.2)         0.074         106 (18.1)         1069 (18.3)         0.006           Annual case volume of ICPR           91 (15.5)         911 (15.6)         911 (15.6)         911 (15.6)           194-276         119 (20.3)         72 794 (24.4)         0.102         119 (20.3)         1168 (20.0)         0.009           277         134 (22.9)         74 611 (25.0)         0.51         134 (22.9)         1402 (24.0)         0.26           Underlying disability            0.046         61 (10.4)         607 (10.4)         0.002           Severe         129 (22.0)         51 559 (17.3)         0.114         129 (22.0)         0.002	Type of hospital	0.40 (40.0)	440.044 (07.0)		0.40 (40.0)	0440 (44.0)	
General nospital         293 (60.0)         163 027 (61.3)         0.007         293 (60.0)         296 (60.0)         0.011           Other hospital         47 (8.0)         33 019 (11.1)         0.112         47 (8.0)         441 (7.5)         0.018           Total hospital         bed number         450 (61.9)         450 (61.9)         4776 (81.7)         ≥1000         106 (18.1)         45 386 (15.2)         0.074         106 (18.1)         1069 (18.3)         0.006           Annual case volume of ICPR         0         91 (15.5)         74 720 (25.1)         91 (15.5)         911 (15.6)         1168 (20.0)         0.009           277         134 (22.9)         74 611 (25.0)         0.051         134 (22.9)         1402 (24.0)         0.026           Underlying disability            133 (22.9)         74 611 (25.0)         0.051         134 (22.9)         0.007           CCI at ICPR         61 (10.4)         35 235 (11.8)         0.046         61 (10.4)         607 (10.4)         0.002           Severe         129 (22.0)         51 559 (17.3)         0.14         129 (22.0)         0.007           CCI at ICPR         69 (4.1)         6.0 (4.1)         0.012         131 (22.4)         129 (22.2)         0.002	Iertiary general nospital	246 (42.0)	112 044 (37.6)	0.007	246 (42.0)	2448 (41.9)	0.011
Other Rospital         47 (8.0)         33 09 (11.1)         0.112         47 (8.0)         44 (1,5)         0.018           Total hospital bed number              0.00         480 (81.9)         252 704 (84.8)         480 (81.9)         4776 (81.7)           ≥1000         106 (18.1)         45 386 (15.2)         0.074         106 (18.1)         1069 (18.3)         0.006           Annual case volume of ICPR          91 (15.5)         911 (15.6)         51 (15.2)         0.321         242 (41.3)         2364 (40.4)         0.015           194–276         119 (20.3)         72 794 (24.4)         0.102         119 (20.3)         1168 (20.0)         0.0026           Underlying disability            0.46 (61 (10.4)         607 (10.4)         0.0022.2)         0.007           Ccl at ICPR         6.9 (4.4)         6.0 (3.9)         0.208         6.9 (4.4)         6.9 (4.1)         0.009           Myocardial infarction         131 (22.4)         54 026 (18.1)         0.102         131 (22.4)         109 (22.2)         0.007           Congestive heart failure         250 (42.7)         117 347 (39.4)         0.062         250 (42.7)         2429 (41.6)         0.021	General hospital	293 (50.0)	153 027 (51.3)	0.027	293 (50.0)	2956 (50.6)	0.011
All Description       480 (81.9)       252 704 (84.8)       480 (81.9)       4776 (81.7)         ≥1000       106 (18.1)       45 386 (15.2)       0.074       106 (18.1)       1069 (18.3)       0.006         Annual case volume of ICPR       0       91 (15.5)       74 720 (25.1)       91 (15.5)       911 (15.6)       911 (15.6)         57-194       242 (41.3)       75 965 (25.5)       0.321       242 (41.3)       2364 (40.4)       0.015         194-276       119 (20.3)       72 794 (24.4)       0.102       119 (20.3)       1148 (20.0)       0.026         Underlying disability       101       35 235 (11.8)       0.046       61 (10.4)       607 (10.4)       0.002         Severe       129 (22.0)       51 559 (17.3)       0.114       129 (22.0)       1300 (22.2)       0.007         Cl at ICPR       6.9 (4.4)       6.0 (3.9)       0.208       6.9 (4.4)       6.9 (4.0)       0.021         Myocardial infarction       131 (22.4)       54 026 (18.1)       0.102       131 (22.4)       1299 (22.0)       0.002         Carebrowascular disease       138 (23.5)       70 417 (23.6)       0.002       138 (23.5)       1386 (23.7)       0.004         Carebrowascular disease       113 (61.81.1)       67 651 (22.7) <td>Tatal begital had sumber</td> <td>47 (8.0)</td> <td>33 019 (11.1)</td> <td>0.112</td> <td>47 (8.0)</td> <td>441 (7.5)</td> <td>0.018</td>	Tatal begital had sumber	47 (8.0)	33 019 (11.1)	0.112	47 (8.0)	441 (7.5)	0.018
1000       140 (81.9)       25 2/04 (84.8)       1400 (81.9)       100 (18.1)         21000       106 (18.1)       45 386 (15.2)       0.074       106 (18.1)       1069 (18.3)       0.006         Annual case volume of ICPR       0-56       91 (15.5)       74 720 (25.1)       91 (15.5)       911 (15.6)       115       57-194       242 (41.3)       75 965 (25.5)       0.321       242 (41.3)       2364 (40.4)       0.015         194–276       119 (20.3)       72 794 (24.4)       0.102       119 (20.3)       1168 (20.0)       0.009         277       134 (22.9)       74 611 (25.0)       0.051       134 (22.9)       1402 (24.0)       0.002         Underlying disability       59 (4.4)       6.0 (3.9)       0.208       6.9 (4.4)       6.9 (4.1)       0.009         Severe       129 (22.0)       51 559 (17.3)       0.114       129 (22.0)       1300 (22.2)       0.007         Cl at ICPR       6.9 (4.4)       6.0 (3.9)       0.208       6.9 (4.4)       6.9 (4.1)       0.002         Mycoardial infarction       131 (22.4)       54 026 (18.1)       0.102       131 (22.4)       1299 (22.2)       0.002         Congestive heart failure       250 (42.7)       117 347 (23.4)       0.066       250 (42.7)		400 (01.0)	252 704 (04 0)		400 (01 0)	4770 (017)	
21000         100 (18,1)         45 358 (16,2)         0.074         106 (18,1)         1059 (18,3)         0.006           Annual case volume of ICPR         0-56         91 (15,5)         74 720 (25,1)         91 (15,5)         911 (15,6)         0.074         0.051         134 (22,9)         0.009           194-276         119 (20,3)         72 794 (24,4)         0.102         119 (20,3)         1168 (20,0)         0.009           277         134 (22,9)         74 611 (25,0)         0.051         134 (22,9)         1402 (24,0)         0.002           Underlying disability           52 35 (11.8)         0.046         61 (10.4)         607 (10.4)         0.002           Severe         129 (22,0)         51 559 (17.3)         0.114         129 (22,0)         1300 (22, 2)         0.002           CCl at ICPR         6.9 (4.4)         6.0 (3.9)         0.208         6.9 (4.4)         6.9 (4.1)         0.002           Myocardial infarction         131 (22.4)         54 026 (18.1)         0.102         131 (22.4)         1299 (22.2)         0.002           Congestive heart failure         250 (42.7)         117 347 (39.4)         0.066         250 (42.7)         2429 (41.6)         0.021           Peripheral vascular disease	<1000	480 (81.9)	252 704 (84.8)	0.074	480 (81.9)	4770 (81.7)	0.000
Anima Case Volume On CPR           0-56         91 (15.5)         74 720 (25.1)         91 (15.5)         911 (15.6)           57-194         242 (41.3)         75 965 (25.5)         0.321         242 (41.3)         2364 (40.4)         0.015           194-276         119 (20.3)         72 794 (24.4)         0.102         119 (20.3)         1168 (20.0)         0.009           277         134 (22.9)         74 611 (25.0)         0.051         134 (22.9)         1402 (24.0)         0.026           Underlying disability             0.046         61 (10.4)         607 (10.4)         0.002           Severe         129 (22.0)         51 559 (17.3)         0.114         129 (22.0)         1300 (22.2)         0.002           CC 1at ICPR         6.9 (4.4)         6.0 (3.9)         0.208         6.9 (4.4)         6.9 (4.1)         0.002           Congestive heart failure         250 (42.7)         117 347 (39.4)         0.066         250 (42.7)         2429 (41.6)         0.021           Peripheral vascular disease         138 (23.5)         70 417 (23.6)         0.002         138 (23.5)         1386 (23.7)         0.004           Cerebrovascular disease         217 (37.0)         112 540 (37.8)         0.015<		100 (18.1)	45 380 (15.2)	0.074	100 (18.1)	1069 (18.3)	0.006
0-50       31 (15.5)       74 720 (25.5)       0.321       242 (41.3)       2364 (40.4)       0.015         194–276       119 (20.3)       72 794 (24.4)       0.102       119 (20.3)       1168 (20.0)       0.009         277       134 (22.9)       74 611 (25.0)       0.051       134 (22.9)       1402 (24.0)       0.026         Underlying disability       59 (22.0)       51 559 (17.3)       0.114       129 (22.0)       1300 (22.2)       0.007         CCl at ICPR       6.9 (4.4)       6.0 (3.9)       0.208       6.9 (4.4)       6.9 (4.1)       0.002         Myocardial infarction       131 (22.4)       54 026 (18.1)       0.102       131 (22.4)       1299 (22.2)       0.002         Congestive heart failure       250 (42.7)       117 347 (39.4)       0.066       250 (42.7)       2429 (41.6)       0.021         Peripheral vascular disease       138 (23.5)       70 417 (23.6)       0.002       138 (23.7)       0.004         Chronic pulmonary disease       256 (60.8)       165 692 (55.6)       0.106       356 (60.8)       3549 (60.7)       <0.001		01 (15 5)	74 700 (25 1)		01 (15 5)	011 /15 6)	
194-276       19 (20.3)       72 794 (24.4)       0.102       119 (20.3)       1168 (20.0)       0.009         277       134 (22.9)       74 611 (25.0)       0.051       134 (22.9)       1402 (24.0)       0.002         Underlying disability          60 (10.4)       607 (10.4)       0.002         Severe       129 (22.0)       51 559 (17.3)       0.114       129 (22.0)       1300 (22.2)       0.007         CC1 at ICPR       6.9 (4.4)       6.0 (3.9)       0.208       6.9 (4.4)       6.9 (4.1)       0.002         Myccardial infarction       131 (22.4)       54 026 (18.1)       0.102       131 (22.4)       1299 (22.2)       0.002         Congestive heart failure       250 (42.7)       117 347 (39.4)       0.066       250 (42.7)       2429 (41.6)       0.021         Peripheral vascular disease       138 (23.5)       70 417 (23.6)       0.002       138 (23.5)       1366 (23.7)       0.004         Cerebrovascular disease       217 (37.0)       112 540 (37.8)       0.015       217 (37.0)       2126 (37.2)       0.001         Dementia       106 (18.1)       67 51 (22.7)       0.120       106 (18.1)       106 (18.2)       <0.001	57-194	242 (41.3)	74 720 (25.1)	0.321	2/12 (/1.3)	2364 (40.4)	0.015
134 (22.9)       74 734 (24.4)       0.102       113 (22.5)       1108 (20.5)       0.005         277       134 (22.9)       74 611 (25.0)       0.051       134 (22.9)       1402 (24.0)       0.026         Underlying disability       Wild to moderate       61 (10.4)       35 235 (11.8)       0.046       61 (10.4)       607 (10.4)       0.002         Severe       129 (22.0)       51 559 (17.3)       0.114       129 (22.0)       1300 (22.2)       0.007         CCl at ICPR       6.9 (4.4)       6.0 (3.9)       0.208       6.9 (4.4)       6.9 (4.1)       0.002         Myocardial infarction       131 (22.4)       54 026 (18.1)       0.102       131 (22.4)       1299 (22.2)       0.002         Congestive heart failure       250 (42.7)       117 347 (39.4)       0.066       250 (42.7)       2429 (41.6)       0.021         Peripheral vascular disease       138 (23.5)       70 417 (23.6)       0.002       138 (23.5)       1386 (23.7)       0.004         Cerebrovascular disease       136 (60.8)       165 692 (55.6)       0.015       217 (37.0)       2126 (37.2)       0.005         Dementia       106 (18.1)       67 651 (22.7)       0.120       106 (18.1)       1061 (18.2)       <0.001	104 276	110 (20.2)	73 303 (23.3)	0.102	110 (20.2)	1169 (20.0)	0.013
Underlying disability       If Yes (22.3)       If Yes (22.3)       If Yes (24.4)       If Yes	277	13/ (22.9)	74 611 (25.0)	0.051	134 (22.9)	1402 (24.0)	0.000
Mild to moderate       61 (10.4)       35 235 (11.8)       0.046       61 (10.4)       607 (10.4)       0.002         Severe       129 (22.0)       51 559 (17.3)       0.114       129 (22.0)       1300 (22.2)       0.007         CCl at ICPR       6.9 (4.4)       6.0 (3.9)       0.208       6.9 (4.4)       6.9 (4.1)       0.009         Myocardial infarction       131 (22.4)       54 026 (18.1)       0.102       131 (22.4)       1299 (22.2)       0.002         Congestive heart failure       250 (42.7)       117 347 (39.4)       0.066       250 (42.7)       2429 (41.6)       0.021         Peripheral vascular disease       138 (23.5)       70 417 (23.6)       0.002       138 (23.5)       1386 (23.7)       0.004         Cerebrovascular disease       217 (37.0)       112 540 (37.8)       0.015       217 (37.0)       2126 (37.2)       0.001         Dementia       106 (18.1)       67 651 (22.7)       0.120       106 (18.1)       1061 (18.2)       <0.001	Underlying disability	104 (22.0)	74 011 (20.0)	0.001	104 (22.0)	1402 (24.0)	0.020
Kind to Hotorite129 (22.0)51 559 (17.3)0.114129 (22.0)1300 (22.2)0.007CCl at ICPR6.9 (4.4)6.0 (3.9)0.2086.9 (4.4)6.9 (4.1)0.009Myocardial infarction131 (22.4)54 026 (18.1)0.102131 (22.4)1299 (22.2)0.002Congestive heart failure250 (42.7)117 347 (39.4)0.066250 (42.7)2429 (41.6)0.021Peripheral vascular disease138 (23.5)70 417 (23.6)0.002138 (23.5)1386 (23.7)0.004Cerebrovascular disease217 (37.0)112 540 (37.8)0.015217 (37.0)2126 (37.2)0.005Dementia106 (18.1)67 651 (22.7)0.120106 (18.1)1061 (18.2)<0.001	Mild to moderate	61 (10.4)	35 235 (11 8)	0.046	61 (10.4)	607 (10.4)	0.002
CCl at ICPR6.9 (4.4)6.0 (3.9)0.2086.9 (4.4)6.9 (4.1)0.009Myocardial infarction131 (22.4)54 026 (18.1)0.102131 (22.4)1299 (22.2)0.002Congestive heart failure250 (42.7)117 347 (39.4)0.066250 (42.7)2429 (41.6)0.021Peripheral vascular disease138 (23.5)70 417 (23.6)0.002138 (23.5)1386 (23.7)0.004Cerebrovascular disease217 (37.0)112 540 (37.8)0.015217 (37.0)2126 (37.2)0.005Dementia106 (18.1)67 651 (22.7)0.120106 (18.1)1061 (18.2)<0.001	Severe	129 (22 0)	51 559 (173)	0 114	129 (22 0)	1300 (22.2)	0.007
Myocardial infarction131 (22.4)54 026 (18.1)0.102131 (22.4)1299 (22.2)0.002Congestive heart failure250 (42.7)117 347 (39.4)0.066250 (42.7)2429 (41.6)0.021Peripheral vascular disease138 (23.5)70 417 (23.6)0.002138 (23.5)1386 (23.7)0.004Cerebrovascular disease217 (37.0)112 540 (37.8)0.015217 (37.0)2126 (37.2)0.005Dementia106 (18.1)67 651 (22.7)0.120106 (18.1)1061 (18.2)<0.001	CCI at ICPB	6.9 (4.4)	6.0 (3.9)	0.208	6.9 (4.4)	6.9 (4.1)	0.009
Congestive heart failure250 (42.7)117 347 (39.4)0.066250 (42.7)2429 (41.6)0.021Peripheral vascular disease138 (23.5)70 417 (23.6)0.002138 (23.5)1386 (23.7)0.004Cerebrovascular disease217 (37.0)112 540 (37.8)0.015217 (37.0)2126 (37.2)0.005Dementia106 (18.1)67 651 (22.7)0.120106 (18.1)1061 (18.2)<0.001	Myocardial infarction	131 (22.4)	54 026 (18.1)	0.102	131 (22.4)	1299 (22.2)	0.002
Peripheral vascular disease138 (23.5)70 417 (23.6)0.002138 (23.5)1386 (23.7)0.004Cerebrovascular disease217 (37.0)112 540 (37.8)0.015217 (37.0)2126 (37.2)0.005Dementia106 (18.1)67 651 (22.7)0.120106 (18.1)1061 (18.2)<0.001	Congestive heart failure	250 (42.7)	117 347 (39.4)	0.066	250 (42.7)	2429 (41.6)	0.021
Cerebrovascular disease217 (37.0)112 540 (37.8)0.015217 (37.0)2126 (37.2)0.005Dementia106 (18.1)67 651 (22.7)0.120106 (18.1)1061 (18.2)<0.001	Peripheral vascular disease	138 (23.5)	70 417 (23.6)	0.002	138 (23.5)	1386 (23.7)	0.004
Dementia106 (18.1)67 651 (22.7)0.120106 (18.1)1061 (18.2)<0.001Chronic pulmonary disease356 (60.8)165 692 (55.6)0.106356 (60.8)3549 (60.7)<0.001	Cerebrovascular disease	217 (37.0)	112 540 (37.8)	0.015	217 (37.0)	2126 (37.2)	0.005
Chronic pulmonary disease356 (60.8)165 692 (55.6)0.106356 (60.8)3549 (60.7)<0.01Rheumatic disease51 (8.7)19 482 (6.5)0.07751 (8.7)520 (8.9)<0.001	Dementia	106 (18.1)	67 651 (22.7)	0.120	106 (18.1)	1061 (18.2)	<0.001
Rheumatic disease51 (8.7)19 482 (6.5)0.07751 (8.7)520 (8.9)<0.01Peptic ulcer disease250 (42.7)116 269 (39.0)0.074250 (42.7)2476 (42.4)0.006Mild liver disease402 (68.6)144 537 (48.5)0.433402 (68.6)3796 (64.9)0.030Diabetes without chronic complication386 (65.9)173 908 (58.3)0.159386 (65.9)3796 (64.9)0.019Diabetes with chronic complication172 (29.4)69 728 (23.4)0.131172 (29.4)1735 (29.7)0.008Hemiplegia or paraplegia180 (30.7)80 907 (27.1)0.077180 (30.7)1788 (30.6)0.003Renal disease174 (29.7)51 400 (17.2)0.272174 (29.7)1707 (29.2)0.008	Chronic pulmonary disease	356 (60.8)	165 692 (55.6)	0.106	356 (60.8)	3549 (60.7)	<0.001
Peptic ulcer disease250 (42.7)116 269 (39.0)0.074250 (42.7)2476 (42.4)0.006Mild liver disease402 (68.6)144 537 (48.5)0.433402 (68.6)3796 (64.9)0.030Diabetes without chronic complication386 (65.9)173 908 (58.3)0.159386 (65.9)3796 (64.9)0.019Diabetes with chronic complication172 (29.4)69 728 (23.4)0.131172 (29.4)1735 (29.7)0.008Hemiplegia or paraplegia180 (30.7)80 907 (27.1)0.077180 (30.7)1788 (30.6)0.003Renal disease174 (29.7)51 400 (17.2)0.272174 (29.7)1707 (29.2)0.008	Rheumatic disease	51 (8.7)	19 482 (6.5)	0.077	51 (8.7)	520 (8.9)	<0.001
Mild liver disease402 (68.6)144 537 (48.5)0.433402 (68.6)3796 (64.9)0.030Diabetes without chronic complication386 (65.9)173 908 (58.3)0.159386 (65.9)3796 (64.9)0.019Diabetes with chronic complication172 (29.4)69 728 (23.4)0.131172 (29.4)1735 (29.7)0.008Hemiplegia or paraplegia180 (30.7)80 907 (27.1)0.077180 (30.7)1788 (30.6)0.003Renal disease174 (29.7)51 400 (17.2)0.272174 (29.7)1707 (29.2)0.008	Peptic ulcer disease	250 (42.7)	116 269 (39.0)	0.074	250 (42.7)	2476 (42.4)	0.006
Diabetes without chronic complication386 (65.9)173 908 (58.3)0.159386 (65.9)3796 (64.9)0.019Diabetes with chronic complication172 (29.4)69 728 (23.4)0.131172 (29.4)1735 (29.7)0.008Hemiplegia or paraplegia180 (30.7)80 907 (27.1)0.077180 (30.7)1788 (30.6)0.003Renal disease174 (29.7)51 400 (17.2)0.272174 (29.7)1707 (29.2)0.008	Mild liver disease	402 (68.6)	144 537 (48.5)	0.433	402 (68.6)	3796 (64.9)	0.030
Diabetes with chronic complication172 (29.4)69 728 (23.4)0.131172 (29.4)1735 (29.7)0.008Hemiplegia or paraplegia180 (30.7)80 907 (27.1)0.077180 (30.7)1788 (30.6)0.003Renal disease174 (29.7)51 400 (17.2)0.272174 (29.7)1707 (29.2)0.008	Diabetes without chronic complication	386 (65.9)	173 908 (58.3)	0.159	386 (65.9)	3796 (64.9)	0.019
Hemiplegia or paraplegia         180 (30.7)         80 907 (27.1)         0.077         180 (30.7)         1788 (30.6)         0.003           Renal disease         174 (29.7)         51 400 (17.2)         0.272         174 (29.7)         1707 (29.2)         0.008	Diabetes with chronic complication	172 (29.4)	69 728 (23.4)	0.131	172 (29.4)	1735 (29.7)	0.008
Renal disease         174 (29.7)         51 400 (17.2)         0.272         174 (29.7)         1707 (29.2)         0.008	Hemiplegia or paraplegia	180 (30.7)	80 907 (27.1)	0.077	180 (30.7)	1788 (30.6)	0.003
	Renal disease	174 (29.7)	51 400 (17.2)	0.272	174 (29.7)	1707 (29.2)	0.008

#### Table 1. Continued

	Before PS Matching			After PS Matching		
Variable	PWH (n = 586)	Control (n = 298 090)	ASD	PWH (n = 586)	Control (n = 5845)	ASD
Cancer	193 (32.9)	82 940 (27.8)	0.109	193 (32.9)	1901 (32.5)	0.008
Moderate or severe liver disease	41 (7.0)	19 468 (6.5)	0.018	41 (7.0)	410 (7.0)	<0.001
Metastatic cancer	43 (7.3)	24 416 (8.2)	0.032	43 (7.3)	430 (7.4)	0.001
Year of ICPR						
2010	38 (6.5)	24 448 (8.2)		38 (6.5)	394 (6.7)	
2011	29 (4.9)	24 140 (8.1)	0.145	29 (4.9)	321 (5.5)	0.024
2012	34 (5.8)	24 572 (8.2)	0.104	34 (5.8)	359 (6.1)	0.014
2013	57 (9.7)	24 035 (8.1)	0.056	57 (9.7)	544 (9.3)	0.014
2014	31 (5.3)	23 665 (7.9)	0.118	31 (5.3)	290 (5.0)	0.015
2015	35 (6.0)	23 776 (8.0)	0.085	35 (6.0)	354 (6.1)	0.003
2016	57 (9.7)	35 823 (12.0)	0.077	57 (9.7)	569 (9.7)	<0.001
2017	70 (11.9)	35 824 (12.0)	0.002	70 (11.9)	670 (11.5)	0.015
2018	97 (16.6)	41 512 (13.9)	0.071	97 (16.6)	998 (17.1)	0.014
2019	138 (23.5)	40 295 (13.5)	0.236	138 (23.5)	1346 (23.0)	0.009

Abbreviations: ASD, absolute value of standardized mean difference; CCI, Charlson comorbidity index; ICPR, in-hospital cardiopulmonary resuscitation; IM, internal medicine; PS, propensity score; PWH, patients with symptomatic HIV infection.

PWH can fall critically ill and be admitted to intensive care units (ICUs). A recent study by Azoulay et al. reported that acute respiratory failure, neurological disorders, and sepsis remain the main conditions that lead HIV-infected patients to the ICU [18]. Moreover, ICU admission due to acute kidney injury and liver disease among HIV-infected patients has increased [18]. Therefore, the management of critically ill patients with HIV infection, especially those in the ICU, is a potentially important issue. IHCA is a major contributor to mortality and morbidity among critically ill patients in the ICU [19], and the outcome of ICPR in PWH might affect their survival outcome. Our study suggested that compared with other critically ill patients who have undergone ICPR, PWH might have a more fatal outcome.

Dysfunction of the immune system is common in critically ill patients, and it can modulate the immune response and worsen patient morbidity and mortality, particularly in sepsis [20]. Moreover, severe lymphopenia has been described in ~30% of patients admitted to the ICU with severe sepsis or septic shock and has been related to high plasma levels of tumor necrosis

Variable	Event, No. (%)	LR or Cox Regression Analysis	<i>P</i> Value		
Discharge alive before PSM					
Control	78 041/298 090 (26.2)	1			
PWH group	142/586 (24.2)	0.90 (0.75–1.09)	.284		
6-mo survival before PSM					
Control	268 846/298 090 (90.2)	1			
PWH group	527/586 (89.9)	0.87 (0.80–0.95)	.001		
1-y survival before PSM					
Control	272 291/298 090 (91.3)	1			
PWH group	535/586 (91.3)	0.87 (0.80–0.95)	.002		
Live discharge after PSM					
Control	1674/5845 (28.6)	1			
PWH group	142/586 (24.2)	0.80 (0.65–0.97)	.024		
6-mo survival after PSM					
Control	5054/5845 (86.5)	1			
PWH group	527/586 (89.9)	1.01 (0.93–1.11)	.768		
1-y survival after PSM					
Control	5139/5845 (87.9)	1			
PWH aroup	535/586 (91.3)	1.02 (0.93-1.11)	.702		

## Table 2. Survival Analysis Before and After PSM

All results were derived from univariable analysis after PSM. The results of logistic regression for discharge alive are presented as ORs with 95% CIs. The results of Cox regression for 6-month and 1-year survival are presented as HRs with 95% CIs.

Abbreviations: LR, logistic regression; OR, odds ratio; PSM, propensity score matching; PWH, patients with symptomatic HIV infection.



Figure 2. Overall survival time after ICPR in the PWH group and the control group using Kaplan-Meier curves after PS matching. Abbreviations: ICPR, in-hospital cardiopulmonary resuscitation; PS, propensity score; PWH, patients with symptomatic HIV infection.

factor-a, interleukin (IL)-6, and IL-10 [21]. Lymphopenia during sepsis was also associated with features of immunosuppression, such as an increased risk of hospital-acquired infections, and was also an independent predictor of poor outcome [22]. In patients with AIDS, lymphopenia could develop due to antibody-dependent cytotoxicity, and 80% of adults and only 50% of children with AIDS have been reported to be lymphopenic [23, 24]. Furthermore, the immunosuppressive peptide of HIV-1 inhibits T- and B-lymphocyte stimulation, and lymphopenia can occur due to the immunosuppressive effect of HIV infection [25]. A previous study reported that lymphopenia was common in patients with cardiac arrest and was associated with poor outcomes after CPR [26]. From these perspectives, it is possible that the immunosuppressive status in PWH with lymphopenia might contribute to the lower live discharge rate than in the control group after ICPR in this study.

Interestingly, long-term survival at 1 year after ICPR was not significantly different between the PWH and control groups in this study. In a retrospective cohort study in France, shortand long-term survival outcomes were related to acute illness severity and immunovirological status at ICU admission in HIV-infected patients [27]. As the South Korean government supports all financial burdens for treatment of HIV infection including ART [15], all PWH continuing ART after ICPR are still supported by the national government if they survive ICPR. Therefore, on continuing ART, our data show that if PWH survive ICPR and are discharged alive from the hospital, they can achieve similar long-term survival outcomes as those without HIV infection.

HIV is a known risk factor for cardiovascular events [28], which include acute myocardial infarction, heart failure, sudden cardiac death, peripheral arterial disease, and stroke [29]. As cardiovascular disease is one of the most common causes of death [30], the PWH group in this study was at potentially

#### Table 3. Multivariable Logistic Regression Model for Live Discharge After ICPR Among the Entire Cohort

Variable	OR (95% CI)	<i>P</i> Value
PWH group (vs control group)	0.78 (0.64–0.95)	.012
Age	0.98 (0.98–0.98)	<.001
Sex, male (vs female)	1.02 (1.00-1.04)	.042
Having a job at ICPR (vs no job)	1.04 (1.02–1.06)	<.001
Residence at ICPR		
Urban area (reference group)	1	
Rural area	0.92 (0.91-0.94)	<.001
Household income level at ICPR		
Q1 (lowest; reference group)	1	
Q2	1.07 (1.04–1.10)	<.001
Q3	1.09 (1.07–1.12)	<.001
Q4	1.10 (1.08–1.13)	<.001
Unknown	1.09 (1.03–1.17)	.006
Main diagnosis at ICPR		
Cardiovascular disease (reference group)	1	
Bespiratory disease	1.36 (1.33–1.38)	< 001
Cancer	0.95 (0.93–0.98)	001
Other	0.69 (0.67-0.72)	< 001
Admitting department	0.00 (0.07-0.72)	<.001
Non IM (reference group)	1	
		001
IIVI Duration of ICDD	0.97 (0.95–0.99)	.001
	1	
y 15.00	1	0.01
15-30	4.01 (3.83–4.20)	<.001
30-45	1.77 (1.69–1.86)	<.001
45-60	1.20 (1.14–1.27)	<.001
	1.03 (0.97–1.10)	.300
lype of hospital		
Tertiary general hospital (reference group)	1	
General hospital	0.62 (0.61–0.64)	<.001
Other hospital	0.73 (0.70–0.76)	<.001
Total hospital bed number		
ÿ	1	
≥1000	1.10 (1.07–1.13)	<.001
Annual case volume of ICPR		
0–56 (reference group)	1	
57–194	0.89 (0.87–0.92)	<.001
194–276	0.88 (0.86–0.92)	<.001
277	0.55 (0.53–0.578)	<.001
Underlying disability		
Mild to moderate (vs no disability)	1.01 (0.98–1.03)	.710
Severe (vs no disability)	1.05 (1.03–1.08)	<.001
Myocardial infarction	1.23 (1.20–1.26)	<.001
Congestive heart failure	1.12 (1.10–1.14)	<.001
Peripheral vascular disease	1.07 (1.04–1.09)	<.001
Cerebrovascular disease	0.97 (0.95–0.99)	.001
Dementia	1.00 (0.98-1.02)	.985
Chronic pulmonary disease	1.37 (1.34–1.39)	<.001
Rheumatic disease	0.93 (0.90-0.96)	<.001
Peptic ulcer disease	1.15 (1.13–1.17)	<.001
Mild liver disease	1.12 (1.10–1.14)	<.001
Diabetes without chronic complication	1 14 (1 12–1 14)	< 0.01
Diabetes with chronic complication	0.96 (0.93-0.99)	.026
Hemiplegia or paraplegia	1 12 (1 09-1 16)	< 0.01
Renal disease	0.91 (0.89_0.94)	< 0.01
Cancer	0.94 (0.92_0.04)	< 0.01
Madarata ar sovere liver disesse	0.54 (0.52-0.57)	< 0.001
Nouerate of Severe liver disease	0.04 (0.02-0.00)	<.001

#### Table 3. Continued

Variable	OR (95% CI)	<i>P</i> Value
Metastatic cancer	0.76 (0.73–0.79)	<.001
Year of ICPR		
2010 (reference group)	1	
2011	1.00 (0.96–1.04)	.869
2012	0.99 (0.95–1.04)	.755
2013	0.87 (0.83-0.91)	<.001
2014	0.88 (0.84-0.92)	<.001
2015	0.87 (0.83-0.91)	<.001
2016	0.90 (0.87-0.94)	<.001
2017	0.88 (0.84–0.91)	<.001
2018	0.82 (0.79-0.85)	<.001
2019	0.86 (0.83–0.89)	<.001

Abbreviations: ICPR, in-hospital cardiopulmonary resuscitation; IM, internal medicine; OR, odds ratio; PWH, patients with symptomatic HIV infection.

higher risk for adverse cardiovascular events compared with the control group, and this might have had a negative effect on the live discharge rate in the PWH group after ICPR.

There are several limitations to this study. First, the immune status or disease severity of HIV infection in the PWH group was not evaluated in this study. This is because the CD4 cell count among patients with AIDS was not available in this study. Second, we cannot access data such as the return of spontaneous circulation after ICPR because there is no ICD-10 code for this in the NHIS database. Third, some important information, such as smoking history, alcohol consumption, and body mass index, was not used in this study due to the limitations of the NHIS database. Lastly, although the data in this study included all ICPR cases across the country, the data were only from South Korea. Therefore, it may be difficult to generalize our findings to other countries because there are different medical systems and cultures. In particular, there have been global variations in mortality in adult patients with HIV infection after initiating antiretroviral treatment [31].

In conclusion, PWH were associated with a lower live discharge rate than those without HIV infection after ICPR. However, long-term survival outcomes up to 6 months and 1 year were not significantly affected by HIV infection. Future studies are needed to improve the live discharge rate after ICPR in PWH.

#### Acknowledgments

*Financial support.* This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Potential conflicts of interest.** All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

*Author contributions.* Tak Kyu Oh designed the study, analyzed the data, interpreted the data, and drafted the manuscript; You Hwan Jo and Kyoung-Ho Song contributed to the acquisition of data; In-Ae Song contributed to the study conceptualization, acquisition of data, and review of the manuscript. All authors have given final approval of the final version of the manuscript.

**Patient consent.** The institutional review board (IRB) of Seoul National University Bundang Hospital approved the study protocol (IRB number: X-2011-651-901), and the National Health Insurance Service (NHIS) permitted data sharing after approval of the study protocol (NHIS-2021-1-266). The requirement for informed consent was waived by the IRB of Seoul National University Bundang Hospital because data analysis was performed retrospectively in an anonymized form.

#### References

- Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol 2007; 37(Suppl 1):S94–102.
- Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001; 66:229–40.
- HIV/AIDS JUNPo. HIV prevention 2020 road map. Accelerating HIV prevention to reduce new infections by 75%. 2017. Available at: https://www.unaids. org/en/resources/documents/2017/hiv-prevention-2020-road-map. Accessed 2 November 2021.
- Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and comorbidityfree life expectancy between insured adults with and without HIV infection, 2000-2016. JAMA Netw Open 2020; 3:e207954.
- Deeks SG, Lewin SR, Ross AL, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med 2016; 22:839–50.
- GBD 2019 HIV Collaborators. Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. Lancet HIV 2021; 8:e633–51.
- Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2015; 2:e438–44.
- Fragkou PC, Dimopoulou D, Latsios G, et al. Transmission of infections during cardiopulmonary resuscitation. Clin Microbiol Rev 2021; 34:e00018–21.
- Mejicano GC, Maki DG. Infections acquired during cardiopulmonary resuscitation: estimating the risk and defining strategies for prevention. Ann Intern Med 1998; 129:813–28.
- Raviglione MC, Battan R, Taranta A. Cardiopulmonary resuscitation in patients with the acquired immunodeficiency syndrome. A prospective study. Arch Intern Med 1988; 148:2602–5.
- Saklayen M, Liss H, Markert R. In-hospital cardiopulmonary resuscitation. Survival in 1 hospital and literature review. Medicine (Baltimore) 1995; 74:163–75.
- Frank TD, Carter A, Jahagirdar D, et al. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV 2019; 6:e831–59.
- Oud L. In-hospital cardiopulmonary resuscitation of patients with human immunodeficiency virus infection: a population-based cohort study of epidemiology and outcomes. J Clin Med Res 2020; 12:233–42.
- Vandenbroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4:e297.
- Kim JM, Kim NJ, Choi JY, Chin BS. History of acquired immune deficiency syndrome in Korea. Infect Chemother 2020; 52:234–44.
- Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79:516–24.
- Mongardon N, Geri G, Deye N, et al. Etiologies, clinical features and outcome of cardiac arrest in HIV-infected patients. Int J Cardiol 2015; 201:302–7.
- Azoulay E, de Castro N, Barbier F. Critically Ill patients with HIV: 40 years later. Chest 2020; 157:293–309.
- Girotra S, Nallamothu BK, Spertus JA, et al. Trends in survival after in-hospital cardiac arrest. N Engl J Med 2012; 367:1912–20.
- Surbatovic M, Vojvodic D, Khan W. Immune response in critically Ill patients. Mediators Inflamm 2018; 2018:9524315.
- Chung KP, Chang HT, Lo SC, et al. Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsis. Shock 2015; 43:569–75.
- Drewry AM, Fuller BM, Skrupky LP, Hotchkiss RS. The presence of hypothermia within 24 hours of sepsis diagnosis predicts persistent lymphopenia. Crit Care Med 2015; 43:1165–9.
- Roger PM, Pradier C, Dellamonica P. Mechanisms of lymphopenia in HIV infection [in French]. Presse Med 1994; 23:89–94.
- Suarez AD, Rao SP, Miller ST. Prevalence of lymphopenia in children with AIDS. Clin Pediatr (Phila) 1994; 33:204–8.
- Denner J, Persin C, Vogel T, Haustein D, Norley S, Kurth R. The immunosuppressive peptide of HIV-1 inhibits T and B lymphocyte stimulation. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:442–50.

- Villois P, Grimaldi D, Spadaro S, et al. Lymphopaenia in cardiac arrest patients. Ann Intensive Care 2017; 7:85.
- 27. Morquin D, Le Moing V, Mura T, et al. Short- and long-term outcomes of HIVinfected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status. Ann Intensive Care **2012**; 2:25.
- Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435–47.
- Hsue PY, Waters DD. Time to recognize HIV infection as a major cardiovascular risk factor. Circulation 2018; 138:1113–5.
- Franco M, Cooper RS, Bilal U, Fuster V. Challenges and opportunities for cardiovascular disease prevention. Am J Med 2011; 124:95–102.
- 31. Johnson LF, Anderegg N, Zaniewski E, et al. Global variations in mortality in adults after initiating antiretroviral treatment: an updated analysis of the International Epidemiology Databases to Evaluate AIDS Cohort Collaboration. AIDS 2019; 33(Suppl 3):S283–94.